CABA290119C00002000
CABA Jan 19 2029 2.00 Call
optionOPRA
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11d | $0.08 | -20.00% | 218 | 216 |
| Nov 20, 2026 | 46d | $0.40 | +53.85% | 21 | 251 |
| Jan 15, 2027 | 102d | $0.41 | -25.45% | 273 | 225 |
| Feb 19, 2027 | 137d | $0.40 | -33.33% | 202 | 79 |
| May 21, 2027 | 228d | $0.50 | -37.50% | 1 | 6 |
| Jan 21, 2028 | 473d | $1.44 | -41.22% | 50 | 531 |
| Jan 19, 2029 | 837d | $1.50 | -11.76% | 17 | 31 |
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un